

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 5, 2022**

**Aileron Therapeutics, Inc.**

(Exact Name of Company as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38130**  
(Commission  
File Number)

**13-4196017**  
(IRS Employer  
Identification No.)

**285 Summer Street, Unit 101**  
**Boston, MA**  
(Address of Principal Executive Offices)

**02210**  
(Zip Code)

**Registrant's telephone number, including area code: (617) 995-0900**

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	ALRN	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

---

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Aileron Therapeutics, Inc. (the “Company”) previously announced on April 25, 2022 that Richard J. Wanstall, the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, notified the Company of his resignation, effective May 6, 2022. On June 5, 2022, the Board of Directors of the Company appointed Manuel Aivado, M.D., Ph.D., the Company’s President and Chief Executive Officer to serve as the Company’s principal financial officer and principal accounting officer. Dr. Aivado, age 52, has served as the President and Chief Executive Officer and as a member of the board of directors since September 2018.

There is no arrangement or understanding between Dr. Aivado and any other person pursuant to which Dr. Aivado was selected as an officer. Dr. Aivado has no family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Dr. Aivado and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Aileron Therapeutics, Inc.**

Date: June 7, 2022

By: /s/ Manuel Aivado

Manuel Aivado, M.D., Ph.D.

President and Chief Executive Officer